Lyell Immunopharma

formerly LyellIPO

Next-Generation CAR-T Cell Therapies for Cancer | Lyell

Public · South San Francisco, United States · Founded 2018 · $884.0M raised

Employees
201–500
Founded
2018
Business Model
B2B
Website
lyell.com
Total Funding
$884.0M
Last Round
$50.0M Venture RoundJul 2025
Rounds
6
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Lyell Immunopharma is a late-stage clinical company advancing next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. Founded in 2018 and headquartered in South San Francisco, Lyell combines proprietary genetic and epigenetic T-cell reprogramming technologies with an in-house manufacturing facility (LyFE Manufacturing Center) to create potent, durable cell therapies designed to deliver lasting remissions with a single treatment.

Summary

Lyell Immunopharma is a Biotech company based in South San Francisco, United States, founded in 2018. It has raised $884.0M in total across 6 rounds, most recently a $50.0M Venture Round in Jul 2025. Investors include GV, ARCH Venture Partners and Foresite Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Venture RoundVenture RoundJul 2025
$50.0M

Sign up to see all 7 events

Funding: Seed through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$2.3BJun 2018
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Lyell Immunopharma on Indexed.vc
<a href="https://indexed.vc/companies/lyell-immunopharma"><img src="https://indexed.vc/api/badge/company/lyell-immunopharma" alt="Lyell Immunopharma on Indexed.vc" width="260" height="76" /></a>